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Abstract: CRISPR/Cas9 system, consisting of clustered regularly interspaced short palindromic repeats 
(CRISPR) and CRISPR-associated (Cas) proteins, is a prokaryotic immune system that confers resistance to        
foreign genetic elements such as those present within plasmids and phages.  A simple version of the CRISPR/      
Cas system, type II CRISPR, has been modified to edit genomes.  By delivering the Cas9 nuclease together with 
a synthetic guide RNA (sgRNA) into cells, genome can be edited at desired loci site.  CRISPR/Cas genome      
editing techniques have been widely implemented in various species and research areas.  In this review, we 
summarize the several applications of CRISPR/Cas9 in the field of drug discovery and development, which       
include target gene screening and editing, drug target screening and validation, generation of animal models       
and treatment of genetic disease, etc.  The defects and improvements of CRISPR/Cas9 technology is discussed 
as well. 
Key words: CRISPR/Cas9 system; genome editing; drug-resistant mutation; target validation; drug          
development 
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Figure 1  Schematic of the RNA-guided Cas9 nuclease and two types of double strand break (DSB)-induced repair mechanism 
 
 
Figure 2  Overview of experiments 
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Figure 4  Schematic of lentiviral-delivered sgRNA library construction and functional screening[21] 
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Figure 5  pgRNA library design[22] 
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